Cardiac Imaging Stress Tests to Evaluate Cardiac Outcomes in Stage I-III Breast Cancer Patients Receiving Near Complete Estrogen Deprivation Therapy, CROWN Study
This clinical trial uses cardiac imaging stress tests to observe the effects of near complete estrogen deprivation therapy (NCED) on the heart in patients with stage I-III breast cancer. Cardiac imaging stress tests involve giving the drugs adenosine and gadolinium by injecting them through a vein. Adenosine makes blood vessels get bigger, and gadolinium is a metal that will help see the heart tissue better. Computed tomography angiogram (CTA) involves giving a chemical dye in the vein called iodinated computed tomography (CT) contrast to see the heart vessels better. An electrocardiogram (ECG) looks at the electrical signals of the heart. Wires called electrodes that have sticky areas are placed on the skin. These wires will be able to read the heart’s electrical signals. This trial may help doctors understand if NCED changes how the heart works.
Inclusion Criteria
- Women age =< 55 who were premenopausal at the time of breast cancer diagnosis; (Premenopausal is defined as per National Comprehensive Cancer Network [NCCN] criteria)
- Planned breast cancer treatment with NCED therapy that includes aromatase inhibitor therapy (or selective estrogen receptor down regulator [SERD]) with medically or surgically induced menopause within 3 months of initiating NCED (hormone receptor [HR]-positive tumor) or, for the cohorts not receiving NCED therapy, within three months of planned chemotherapy, surgery or radiation. Index date for three months is defined as final date of treatment with chemotherapy, surgery, or radiation which ever happens last (HR-negative tumor). Treatment with a Gonadotropin Releasing Hormone (GnRH) agonist for fertility preservation during chemotherapy is allowed and is not considered part of the NCED antineoplastic therapy
- Women with human epidermal growth factor-2 (HER2) negative and women with human epidermal growth factor-2 (HER2) positive breast cancer are eligible
- Treatment with cyclin-dependent kinase (CDK)-inhibitor, PARP inhibitor, immunotherapy or biologic (non-chemotherapy) agent as part of anti-neoplastic treatment plan is allowed. These agents are not considered chemotherapy
- Treatment with selective-estrogen receptor degrader (SERD) rather than aromatase inhibitor is allowed
- Diagnosed with stage I-III breast cancer
- Eastern Cooperative Oncology Group (ECOG) performance status of 0-2
- Patients with concurrent malignancies are eligible as long as therapies and disease course for these are reasonably expected to not impact cardiovascular function. (Examples of eligible malignancies include: papillary/follicular thyroid cancer, basal cell carcinoma of the skin, squamous cell carcinoma of the skin, in-situ and early stage cervical cancers, etc.)
- Patients with prior corona virus disease 2019 (COVID-19) are eligible if they have recovered from the illness and are free of COVID-related symptoms other than allowable persistent symptoms: loss of taste and smell and/or grade 1 fatigue
- Ability to understand and the willingness to sign an institutional review board (IRB)-approved informed consent document (either directly or via a legally authorized representative)
- The study will allow up to 30% of patients with MRI non-compatible breast expanders recognizing that baseline CMR will be outside of imaging window. Note: Registration of these participants will require study primary investigator (PI) approval (Dr. Jordan or Dr. Thomas).
Exclusion Criteria
- History of allergic reactions attributed to compounds of similar chemical or biologic composition to adenosine
- Active wheezing
- Those with contraindications for MRI such as ferromagnetic cerebral aneurysm clips or other intracranial metal, pacemakers, defibrillators, functioning neurostimulator devices or other implanted electronic devices, or some breast expanders
- Uncontrolled intercurrent illness including, but not limited to ongoing or active infection, symptomatic congestive heart failure, unstable angina pectoris, cardiac arrhythmia, or psychiatric illness/social situations that would limit compliance with study requirements
- Pregnant women are excluded from this study. Because some methods of birth control are not 100% reliable, a pregnancy test is required, unless the patient has undergone either a bilateral oophorectomy, hysterectomy or both
- Coronary revascularization in the past 6 months or known severe multi-vessel coronary artery disease (CAD) previously determined to be not amendable to mechanical intervention
- Ongoing, unrelieved symptoms thought to represent cardiac ischemia and requiring immediate cardiac catheterization
- Allergy or prior sensitivity to gadolinium or other contrasting agents or their excipients
- Men with breast cancer
- Known chronic renal insufficiency or chronic electrolyte abnormalities as determined by the treating physician
Additional locations may be listed on ClinicalTrials.gov for NCT05309655.
Locations matching your search criteria
United States
North Carolina
Durham
Winston-Salem
Virginia
Richmond
PRIMARY OBJECTIVE:
I. To determine the 24-month difference in stress myocardial blood flow during adenosine stress cardiovascular magnetic resonance imaging (CMR) in premenopausal women treated with NCED for high-risk hormone receptor-positive breast cancer and in premenopausal women treated without NCED for hormone receptor-negative breast cancer.
SECONDARY OBJECTIVES:
I. To determine the 12-month difference in stress myocardial blood flow during adenosine stress cardiovascular magnetic resonance imaging (CMR) in premenopausal women treated with NCED for high-risk hormone receptor-positive breast cancer and in premenopausal women treated without NCED for hormone receptor-negative breast cancer.
II. To determine the 12-month and 24-month difference in aortic stiffness (thoracic pulse wave velocity and distensibility) with CMR in premenopausal women treated with an NCED for high-risk hormone receptor-positive breast cancer and in premenopausal women treated without NCED for hormone-receptor-negative breast cancer.
III. To determine the association of stress CMR myocardial blood flow with total coronary plaque burden from coronary computed tomography angiography (at baseline and 24 month difference) and difference in variability in these measures in premenopausal women treated with NCED for high-risk hormone receptor-positive breast cancer and in premenopausal women treated without NCED for hormone receptor- negative breast cancer.
IV. To determine the 12-month and 24-month difference in myocardial perfusion reserve in premenopausal women treated with NCED for high-risk hormone receptor-positive breast cancer and in premenopausal women treated without NCED for hormone-receptor-negative breast cancer.
V. To develop predictive models to identify women at highest risk for developing deficits in myocardial blood flow in premenopausal women treated with NCED for high-risk hormone receptor-positive breast cancer.
VI. To monitor disease outcomes, in particular invasive-breast cancer free survival and to assess if any changes in anti-neoplastic therapy occur on the basis cardiovascular diagnoses generally or specifically due to CROWN study results.
EXPLORATORY OBJECTIVES:
I. To determine the association of stress CMR myocardial blood flow with low coronary plaque burden from coronary computed tomography angiography (at baseline and 24 month difference) and difference in variability in these measures in premenopausal women treated with NCED for high-risk hormone receptor-positive breast cancer and in premenopausal women treated without NCED for hormone receptor- negative breast cancer.
II. To determine the association of stress CMR myocardial blood flow with high coronary plaque burden from coronary computed tomography angiography (at baseline and 24 month difference) and difference in variability in these measures in premenopausal women treated with NCED for high-risk hormone receptor-positive breast cancer and in premenopausal women treated without NCED for hormone receptor- negative breast cancer.
III. To determine the association of stress CMR myocardial blood flow with calcified coronary plaque burden from coronary computed tomography angiography (at baseline and 24 month difference) and difference in variability in these measures in premenopausal women treated with NCED for high-risk hormone receptor-positive breast cancer and in premenopausal women treated without NCED for hormone receptor- negative breast cancer.
IV. To determine the association of stress CMR myocardial blood flow with non-calcified coronary plaque burden from coronary computed tomography angiography (at baseline and 24 month difference) and difference in variability in these measures in premenopausal women treated with NCED for high-risk hormone receptor-positive breast cancer and in premenopausal women treated without NCED for hormone receptor- negative breast cancer.
V. To examine the relationship between blood biomarkers and clinical outcomes in premenopausal women treated with NCED for high-risk hormone receptor-positive breast cancer and in premenopausal women treated without NCED for hormone receptor- negative breast cancer.
VI. To measure physical activity over time in premenopausal women treated with NCED for high-risk hormone receptor-positive breast cancer and in premenopausal women treated without NCED for hormone receptor- negative breast cancer.
OUTLINE:
Patients receive adenosine and gadolinium intravenously (IV) and undergo CMR imaging and blood specimen collection at baseline, year 1 and year 2. Patients also receive CT contrast IV and undergo CTA, as well as ECG at baseline and year 2. Patients may undergo orbital x-rays throughout the study.
After completion of study, patients are followed at 30 days and then yearly for up to 5 years.
Trial PhaseNo phase specified
Trial Typetreatment
Lead OrganizationDuke University Medical Center
Principal InvestigatorAlexandra Thomas
- Primary IDWFBCCC 98122
- Secondary IDsNCI-2022-06768, CROWN Study, IRB00083573
- ClinicalTrials.gov IDNCT05309655